Insights from 2023 EHA® Annual Meeting

 

Leukemia
10:42

Insights from 2023 EHA® Annual Meeting

Updated Data for Ziftomenib in Adults With NPM1-Mutated R/R AML

FEATURING Amir Fathi
  • 241 views
  • August 8, 2023
16:16

Insights from 2023 EHA® Annual Meeting

Experts Discuss Key Updates in CLL From EHA and iCML

FEATURING Susan O'Brien, Catherine Coombs
  • 446 views
  • August 3, 2023
  • 3
06:28

Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "Venetoclax + Obinutuzumab for Previously Untreated CLL - 6-Year Results of the Randomized CLL14 Study"

FEATURING Othman Al-Sawaf
  • 670 views
  • July 17, 2023
07:51

Insights from 2023 EHA® Annual Meeting

EHA® 2023 Insights: "4-Year Follow-Up From the Randomized Phase 2 VISION/HO141 Trial - Time-Limited Venetoclax & Ibrutinib for Patients With R/R CLL Who Have Undetectable MRD"

FEATURING Arnon Kater
  • 82 views
  • June 14, 2023
  • 1